Antagonists to GRPR labelled with lutetium-177 were evaluated in preclinical studies on mice bearing prostate cancer xenografts, demonstrating a promising therapeutic efficacy with extended survival of the mice receiving the radiolabelled peptide [21,22]. The gene discussed is GRPR; the disease is Familial prostate cancer.